 ITEM 1. DESCRIPTION OF BUSINESS 

&#160;

FORWARD-LOOKING STATEMENTS

&#160;

This annual report contains forward-looking statements. These statements relate to future events or our future financial performance. These statements often can be identified by the use of terms such as &#34;may,&#34; &#34;will,&#34; &#34;expect,&#34; &#34;believe,&#34; &#34;anticipate,&#34; &#34;estimate,&#34; &#34;approximate&#34; or &#34;continue,&#34; or the negative thereof. We intend that such forward-looking statements be subject to the safe harbors for such statements. We wish to caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. Any forward-looking statements represent management's best judgment as to what may occur in the future. However, forward-looking statements are subject to risks, uncertainties and important factors beyond our control that could cause actual results and events to differ materially from historical results of operations and events and those presently anticipated or projected. We disclaim any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statement or to reflect the occurrence of anticipated or unanticipated events.

&#160;

Our Business 

&#160;

Altair International Corp. (&#8220;Altair&#8221;) is a development stage company that was incorporated in Nevada on December 20, 2012. The Company has recently entered into a strategic alliance with Cure Pharmaceutical Corporation (&#8220;CURE&#8221;), a California company engaged in the development of oral thin film (&#8220;OTF&#8221;) for the delivery of nutraceutical, over-the-counter and prescription products. Currently this alliance is comprised of an Exclusive License and Distribution Agreement for CURE&#8217;s Sildenafil (commonly known as Viagra) Products throughout Asia, Brazil, the Middle East and Canada while a Joint Venture Agreement for the procurement of converting and packaging equipment specific for oral thin film products has been proposed through a Letter of Intent. In addition, Altair and Cure have agreed to enter into further joint ventures or other business relationships for the purpose of completing the development and marketing of additional products, and for license and distribution agreements for additional Cure products such as aspirin, sleep-aid, topical muscle and joint pain relief, and electrolytes delivered through OTF or other methods.

&#160;

The Company had previously planned to commence operations in the architectural field and to be responsible for the concept architectural vision of future private and public buildings as well as municipal organized public areas. This plan was abandoned in the 2015 fiscal year in favor of the business operations described above.

&#160;

&#160;

&#160; &#160; 4 | Page 

&#160;

